A study placed 251 patients (aged 12 to 17) with moderate-to-severe atopic dermatitis (AD) into three groups: (1) patients receiving dupilumab every two weeks, (2) patients receiving dupilumab every four weeks, and (3), patients receiving placebo every two weeks.
In each group, patients experienced improvements in their AD, as well as improvement in quality of life scales.